HOOKIPA to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Securities Global Biopharma Conference from February 14-16, 2023. The company plans to deliver a corporate presentation on February 14, 2023, at 10:00 AM EST. Interested parties can access the live webcast and archived replay through the Investors & Media section of HOOKIPA’s website.

HOOKIPA is focused on developing innovative immunotherapies utilizing its proprietary arenavirus platform. Their pipeline includes therapies targeting Human Papillomavirus 16-positive cancers and prostate cancers, along with collaborations with Roche and Gilead on cancer and viral infections.

NEW YORK and VIENNA, Austria, Feb. 07, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual SVB Securities Global Biopharma Conference, February 14 - 16, 2023.

Corporate Presentation: Tuesday, February 14, 2023 at 10:00 AM EST

The webcast of the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media Enquiries	Investors
Instinctif Partners	Matt Beck
hookipa@instinctif.com	Executive Director - Investor Relations
+44 (0)20 7457 2020	matthew.beck@hookipapharma.com +1 (917) 209-6886

 

FAQ

When is HOOKIPA's presentation at the SVB Securities Global Biopharma Conference?

HOOKIPA's presentation is scheduled for February 14, 2023, at 10:00 AM EST.

Where can I watch HOOKIPA's corporate presentation?

The corporate presentation can be accessed live and as a replay on HOOKIPA's website in the Investors & Media section.

What is HOOKIPA Pharma focusing on?

HOOKIPA Pharma is developing novel immunotherapies based on its proprietary arenavirus platform to target various cancers and viral infections.

Who is collaborating with HOOKIPA on their immunotherapeutics?

HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers and with Gilead for potential cures of HBV and HIV.

What types of cancers is HOOKIPA targeting with its therapies?

HOOKIPA is targeting Human Papillomavirus 16-positive cancers and prostate cancers with its investigational arenaviral immunotherapies.